PPARA and metabolic dysfunction-associated steatotic liver disease: The gene-specific deletion of PPARα promotes NAFLD, whereas the expression of PPARα and the use of PPARα agonists, such as fenofibrate, prevent hepatic steatosis, inflammation, oxidative stress, and liver injury in HFD-fed animals [66,68,69].